3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
6
Head & Neck
2
Gynecologic
2
Breast
2
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Conditions
Carcinoma, Renal Cell
62
Prostatic Neoplasms
35
Kidney Neoplasms
18
Carcinoma, Transitional Cell
17
Melanoma
15
Urinary Bladder Neoplasms
14
Neoplasm Metastasis
12
Carcinoma, Non-Small-Cell Lung
12
Clear-cell metastatic renal cell carcinoma
11
Colorectal Neoplasms
9
Neoplasms
8
Carcinoma, Hepatocellular
8
Squamous Cell Carcinoma of Head and Neck
7
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
6
Lung Neoplasms
6
Uterine Cervical Neoplasms
5
Stomach Neoplasms
5
Pancreatic Neoplasms
5
Urogenital Neoplasms
4
Small Cell Lung Carcinoma
4
Endometrial Neoplasms
4
Carcinoma, Merkel Cell
4
Urethral Neoplasms
3
Penile Neoplasms
3
Neuroblastoma
3
Liver Neoplasms
3
Brain Neoplasms
3
Wilms Tumor
2
Ureteral Neoplasms
2
Interventions
Radiotherapy
2
Ifosfamide
2
Filgrastim
2
Doxorubicin
2
belinostat
1
Ritonavir
1
Ipilimumab
1
Indinavir
1
Fluorouracil
1
Chemotherapy, Adjuvant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
Ipilimumab
×
Genitourinary
×
Clear all
NCT03752398
2024-07-05
DUET-3
Xencor, Inc.
Phase 1
Completed
198 enrolled